News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Neoadjuvant Nivo+ Ipi vs ChT in Resectable NSCLC
medpagetoday.com
Jan 11, 2025, 09:17

Neoadjuvant Nivo+ Ipi vs ChT in Resectable NSCLC

Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared on X:

“Neoadjuvant Nivo+ Ipi vs ChT in Resectable NSCLC (CM816) Better in terms of pCR, 3y-EFS, and OS BUT The rate of surgery cancellations due to early progression is 16%. ( Nivo+ChT: 6.7%). While pseudoprogression is a factor, such high early progression rates may prevent Nivo+Ipi from routine use.”

Neoadjuvant Nivo+ Ipi vs ChT in Resectable NSCLC

Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer | Journal of Clinical Oncology

Authors: Mark M. Awad, Patrick M. Forde, Nicolas Girard, Jonathan Spicer, Changli Wang, Shun Lu, Tetsuya Mitsudomi, Enriqueta Felip, Stephen R. Broderick, Scott J. Swanson, Julie Brahmer, Keith Kerr, Gene B. Saylors, Ke-Neng Chen, Vishwanath Gharpure, Jaclyn Neely, David Balli, Nan Hu, and Mariano Provencio Pulla.

Neoadjuvant Nivo+ Ipi vs ChT in Resectable NSCLC

 

 

cancer Changli Wang David Balli Enriqueta Felip Gene B. Saylors Jaclyn Neely Jonathan Spicer Julie Brahmer Ke-Neng Chen Keith Kerr Mariano Provencio Pulla Mark M. Awad Nan Hu Nicolas Girard OncoDaily Oncology Patrick M Forde Scott J. Swanson Shun Lu Stephen R Broderick Tetsuya Mitsudomi Vishwanath Gharpure Yakup Ergün
Special Coverage
Blog
Apr 15, 2025, 17:17
Sally Wolf: I'm in here, can anyone see me?
Blog
Apr 15, 2025, 17:01
Nicholas Hornstein: Aspirin can prevent colon cancer?
Blog
Apr 15, 2025, 17:00
Cancer Council NSW awarded funding to 13 cutting-edge cancer research projects - Children's Cancer Institute
Blog
Apr 15, 2025, 16:16
Farrah Bashir: Very informative session on CAR T cell therapy during SIOP Asia 2025
Blog
Apr 15, 2025, 16:16
Latifah Alarfaj: A pleasure to attend the SIOP Asia 2025
Blog
Apr 15, 2025, 15:50
Wen Shen Looi: Exciting time at SIOP Asia 2025 in Riyadh with old friends
Blog
Apr 15, 2025, 15:43
Tsetsegsaikhan Batmunkh: It was an incredible honor to participate in the SIOP Asia 2025 conference
Blog
Apr 15, 2025, 15:31
Ruzanna Papyan: Feeling inspired after an incredible SIOP Asia 2025 in Riyadh
Science
Apr 15, 2025, 15:26
Miguel Bronchud: How to Sequence Therapies in a Patient With Relapsed CLL
Blog
Apr 15, 2025, 15:16
Carmen Uscatu: My dream is to establish a comprehensive childhood cancer center at Marie Curie Children’s Hospital
Insight
Apr 15, 2025, 15:11
Benoit Rousseau: Editorial on the prognostication of stage III colon cancer with Andrea Cercek
Blog
Apr 15, 2025, 15:10
Samantha Siegel: Onco-Primary Approach to Symptoms in Survivorship